BLB&B Advisors LLC Buys 400 Shares of Edwards Lifesciences Co. (NYSE:EW)

BLB&B Advisors LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,520 shares of the medical research company’s stock after purchasing an additional 400 shares during the quarter. BLB&B Advisors LLC’s holdings in Edwards Lifesciences were worth $298,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. Allspring Global Investments Holdings LLC grew its position in Edwards Lifesciences by 4.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock worth $31,603,000 after acquiring an additional 14,087 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Edwards Lifesciences by 151.2% in the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock valued at $1,923,000 after purchasing an additional 12,112 shares in the last quarter. Cetera Advisors LLC raised its position in Edwards Lifesciences by 175.1% in the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after purchasing an additional 24,242 shares during the last quarter. Financial Sense Advisors Inc. acquired a new position in Edwards Lifesciences during the 1st quarter worth $975,000. Finally, BDF Gestion bought a new position in Edwards Lifesciences in the 2nd quarter valued at $5,148,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EW. Evercore ISI cut their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Oppenheimer reissued an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Canaccord Genuity Group reduced their price objective on shares of Edwards Lifesciences from $77.00 to $66.00 and set a “hold” rating on the stock in a research note on Monday, October 7th. Finally, Truist Financial dropped their target price on shares of Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Fifteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $75.81.

Insider Transactions at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,133,916.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock valued at $1,099,238 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $70.63 on Thursday. The firm’s 50 day moving average price is $68.04 and its two-hundred day moving average price is $78.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market cap of $42.56 billion, a P/E ratio of 30.44, a PEG ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same period in the prior year, the business earned $0.66 EPS. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.